Kindred prices IPO in middle of expected range

Kindred Biosciences (KIN) prices its 7.5M share IPO at $7 each, the middle of the expected $6-$8 range.

From IPOdesktop's IPO preview: KIN is a development stage biopharmaceutical company focused on saving and improving the lives of pets ... KIN's lead product candidates are CereKin for the treatment of osteoarthritis pain and inflammation in dogs; AtoKin for the treatment of atopic dermatitis in dogs; and SentiKin for the treatment of post-operative pain in dogs."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs